Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Lung Neoplasms 14Carcinoma, Medullary 14Neoplasm Metastasis 12Neoplasms 10Thyroid Neoplasms 8Breast Neoplasms 8Glioma 6Prostatic Neoplasms 5Glioblastoma 5Squamous Cell Carcinoma of Head and Neck 4Gliosarcoma 4Colorectal Neoplasms 4Brain Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Thyroid Cancer, Papillary 2Stomach Neoplasms 2Recurrence 2Rectal Neoplasms 2Pleural Effusion 2Kidney Neoplasms 2Familial medullary thyroid carcinoma 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Disease Progression 2

Interventions

vandetanib 1trametinib 1pralsetinib 1lenvatinib 1larotrectinib 1entrectinib 1donafenib 1dabrafenib 1cabozantinib 1apatinib 1anlotinib 1Sorafenib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Thyroid Gland Carcinoma × vandetanib × Clear all
NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

West China Hospital

Phase 2 Recruiting
75 enrolled
Head & Neck

Locally Advanced Thyroid Gland Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡